IRIS
LA MONICA, Silvia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.674
EU - Europa 3.560
AS - Asia 3.527
SA - Sud America 579
AF - Africa 214
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 12.564
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.583
SG - Singapore 1.399
CN - Cina 1.265
IT - Italia 909
IE - Irlanda 573
SE - Svezia 527
BR - Brasile 475
FI - Finlandia 422
DE - Germania 335
HK - Hong Kong 275
VN - Vietnam 214
UA - Ucraina 154
NL - Olanda 139
ZA - Sudafrica 118
GB - Regno Unito 108
TR - Turchia 93
IN - India 82
RU - Federazione Russa 80
FR - Francia 79
AT - Austria 65
CA - Canada 63
CI - Costa d'Avorio 62
BE - Belgio 47
AR - Argentina 41
ID - Indonesia 30
PL - Polonia 29
BD - Bangladesh 23
JP - Giappone 22
ES - Italia 21
KR - Corea 19
CZ - Repubblica Ceca 18
CO - Colombia 17
EC - Ecuador 17
PK - Pakistan 17
IQ - Iraq 16
MX - Messico 16
IR - Iran 12
UZ - Uzbekistan 10
LT - Lituania 9
MA - Marocco 9
HU - Ungheria 8
KE - Kenya 8
VE - Venezuela 7
CL - Cile 6
PY - Paraguay 6
AL - Albania 5
AZ - Azerbaigian 5
KG - Kirghizistan 5
LU - Lussemburgo 5
PS - Palestinian Territory 5
TN - Tunisia 5
CH - Svizzera 4
NP - Nepal 4
NZ - Nuova Zelanda 4
RO - Romania 4
UY - Uruguay 4
BO - Bolivia 3
DO - Repubblica Dominicana 3
EG - Egitto 3
IL - Israele 3
JO - Giordania 3
PE - Perù 3
SY - Repubblica araba siriana 3
AU - Australia 2
CY - Cipro 2
DK - Danimarca 2
DZ - Algeria 2
ET - Etiopia 2
EU - Europa 2
HR - Croazia 2
JM - Giamaica 2
KW - Kuwait 2
KZ - Kazakistan 2
LB - Libano 2
LK - Sri Lanka 2
MD - Moldavia 2
OM - Oman 2
PA - Panama 2
QA - Qatar 2
RS - Serbia 2
SI - Slovenia 2
SN - Senegal 2
TJ - Tagikistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AD - Andorra 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
GA - Gabon 1
GR - Grecia 1
HN - Honduras 1
LV - Lettonia 1
MY - Malesia 1
Totale 12.557
Salva come PNG Salva come JPEG
Città #
Singapore 705
Dallas 616
Dublin 571
Chandler 499
Ashburn 487
Santa Clara 317
Ann Arbor 314
Beijing 314
Parma 283
Hong Kong 274
Jacksonville 186
Boardman 169
Dearborn 167
Nanjing 116
Shanghai 113
Johannesburg 112
Los Angeles 111
Munich 106
New York 96
Chicago 90
Princeton 89
Hefei 87
Izmir 82
Ho Chi Minh City 77
Milan 76
Abidjan 62
Wilmington 57
Bremen 56
San Mateo 55
Nanchang 51
Vienna 50
Kunming 48
Helsinki 47
Shenyang 47
São Paulo 44
Buffalo 40
Tianjin 37
Hanoi 36
Marseille 34
Bologna 33
Brussels 30
Toronto 30
Columbus 29
Des Moines 29
Hebei 29
Jinan 29
Guangzhou 28
Moscow 28
Seattle 27
Jakarta 26
Turku 26
Rome 24
Warsaw 24
London 22
Changsha 21
Grafing 21
Modena 21
Pune 21
The Dalles 21
Woodbridge 21
Nuremberg 20
Council Bluffs 19
Norwalk 19
Redmond 19
Reggio Emilia 19
Rio de Janeiro 19
Amsterdam 18
Phoenix 18
Seoul 18
Denver 17
Jiaxing 17
Frankfurt am Main 16
Houston 16
Brooklyn 15
Fremont 15
Brasília 13
Leawood 13
Brescia 12
Manchester 12
Montreal 12
Tokyo 12
Wayne 12
Haiphong 11
Poplar 11
San Francisco 11
Augusta 10
Belo Horizonte 10
Boston 10
Chennai 10
Florence 10
Redwood City 10
Stockholm 10
Brno 9
Tashkent 9
Wuhan 9
Bari 8
Campinas 8
Dong Ket 8
Düsseldorf 8
Lanzhou 8
Totale 7.782
Salva come PNG Salva come JPEG
Nome #
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 225
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 218
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 204
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 203
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 200
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 183
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 179
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 177
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 169
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 169
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 166
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 162
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 162
Characterization of gefitinib uptake in NSCLC cell lines 161
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 161
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 158
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 154
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 154
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 154
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 154
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 150
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 147
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 146
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 146
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 144
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 144
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 143
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 143
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 142
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 142
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 139
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 137
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 135
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 135
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 133
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 133
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 133
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 133
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 131
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 131
Physico-chemical characterization and biological evaluation of two fibroin materials 130
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 129
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 127
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 126
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 126
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 124
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 123
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 122
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 119
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 119
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 116
Interaction between Occupational and Non-Occupational Arsenic Exposure and Tobacco Smoke on Lung Cancerogenesis: A Systematic Review 114
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 112
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 112
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 112
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 111
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 111
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation 110
Down-Modulation of Erk Protein Kinase Activity Inhibits Vascular Endothelial Growth Factor (VEGF) Secretion by human Myeloma Cell Lines 109
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 109
PD-L1 level is up-regulated in NSCLC cells after pemetrexed treatment 107
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 106
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 105
Osteopontin is produced by human multiple myeloma cells 104
Multiple myeloma patient with unusual extramedullary involvement 104
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 102
Synergistic effect of PI3K and FAK inhibition in squamous lung cancer cells with reduced PTEN level 101
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease 101
Successful regrowth of retinal neurons when cultured interfaced to carbon nanotube platforms 100
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 99
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 98
Interaction between occupational radon exposure and tobacco smoke: a systematic review 97
Role of cell gefitinib metabolism in the response of NSCLC cell lines to gefitinib. 95
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 94
The maintenance of gefitinib inhibits migration and epithelial-mesenchimal transition of Non-small cell lung cancer cell lines that have become resistant after prolonged gefitinib treatment 94
Multiple myeloma patient with unusual extramedullary involvement 93
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines 92
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 91
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 88
Effect of letrozole and sorafenib on cell proliferation and apoptosis of MCF-7/AROM-1 breast cancer cell line 87
Overcoming resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer cell lines 87
Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry 87
Synergistic activity of letrozole and sorafenib on breast cancer cells 86
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 86
Optimizing EGFR inhibitor treatment in non small cell lung cancer 85
Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells 84
Targeting FGFR1 pathway in squamous cell lung cancer 83
Generation and characterization of a new preclinical mouse model of egfr-driven lung cancer with met-induced osimertinib resistance 83
Erlotinib potentiates Cetuximab-dependent call citotoxicity in EGFR wild type NSCLC cell lines 83
Amino acid signaling through the mammalian target of rapamycin (mTOR) pathway: Role of glutamine and of cell shrinkage 81
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 80
Evaluation of gefitinib maintenance in an EGFR-mutant NSCLC cell line with acquired resistance 80
Preclinical study assessing effects of gefitinib continuation after development of gefitinib resistance in NSCLC with activating EGFR mutations 80
RANKL is critically involved in the physiopathology of multiple myeloma 79
RANKL is critically involved in the physiopathology of multiple myeloma 77
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines. 74
Evaluation of gefitinib maintenance in an EGFR-mutant NSCL cell line with acquired resistance 73
New therapeutic strategies for malignant pleural mesothelioma 73
Erlotinib potentiates Cetuximab-dependent cell citotoxicity in EGFR wild-type NSCLC cell lines 69
Micro-fragmented Fat Inhibits the Progression of Human Mesothelioma Xenografts in Mice 66
Totale 12.215
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.565
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.565
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021424 0 0 0 0 0 16 54 40 101 26 135 52
2021/2022574 36 15 52 41 20 25 88 50 31 22 40 154
2022/20232.208 211 234 150 141 197 244 45 142 687 17 101 39
2023/20241.003 35 73 34 47 81 185 85 81 44 55 105 178
2024/20252.898 137 136 185 197 279 281 204 144 338 241 261 495
2025/20263.396 517 583 853 585 815 43 0 0 0 0 0 0
Totale 12.755